A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 30, 2021

Primary Completion Date

June 26, 2025

Study Completion Date

June 30, 2026

Conditions
Phlebotomy Dependent Polycythemia Vera
Interventions
DRUG

sapablursen

Sapablursen will be administered by SC injection.

Trial Locations (18)

2298

Calvary Mater Newcastle Hospital, Waratah

2640

Border Medical Oncology Research Unit, Albury

6005

The Perth Blood Institute, West Perth

35249

O'Neal Comprehensive Cancer Center University of Alabama at Birmingham, Birmingham

44195

Cleveland Clinic Foundation, Cleveland

77030

University of Texas MD Anderson Cancer Center, Houston

85054

Mayo Clinic Hospital, Phoenix

91011

Norris Comprehensive Cancer Center, Los Angeles

92868

University of California Irvine, Orange

07601

John Theurer Cancer Center, Hackensack

H4A 3J1

McGill University Health Centre, Montreal

20-081

Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie, Klinika Hematoonkologii i Transplantacji Szpiku, Lublin

76-200

Wojewódzki Szpital Specjalistyczny Sp. z o.o., Słupsk

87-100

MICS Centrum Medyczne Toruń, Torun

LN2 5QY

United Lincolnshire Hospitals NHS Trust, Lincoln

OX37LE

Oxford University Hospitals NHS Foundation Trust, Oxford

NW1 2PG

University College London Hospitals NHS Foundation Trust, London

B71 4HJ

Sandwell and West Birmingham Hospitals NHS Trust, West Bromwich

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY